ReviewThyroid research2025
Myxedema coma: challenges and future directions, a systematic survey and review.
Review in Thyroid research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Rescue Mastectomy in a Patient With Locally Advanced Triple-Negative Breast Cancer and Severe Biochemical Hypothyroidism: A Multidisciplinary Ethical and Surgical Dilemma.Case reports in oncological medicine · 2026Article
- From the Popoveniuc Score to Therapeutic Protocols: A Comprehensive Review of Myxedema Coma.Cureus · 2026Review
- Myxedema Coma as the Initial Presentation of Undiagnosed Hypothyroidism: A Rare but Reversible Emergency.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There was no systematic study on myxedema coma (MC), this review summarizes clinical research on MC conducted over the past 20 years. Publications from 2004 to 2024 were retrieved from databases and included. A total of 584 published cases and 114 unpublished cases of MC were systematically analyzed. The estimated incidence rate of MC was 0.12 (95% confidence interval [CI], 0.10%-0.14%) per million per year. Precipitating factors were identified in 77.6% (95%CI: 73.7%-81.5%) of patients with MC. The overall mortality rate was 38.8% (271/698, 95%CI: 34.9%-42.7%), with shock and multiple organ failure (MOF) being the most common causes of death. The results demonstrated that 88.9% (95%CI: 86.9%-90.9%) of patients with confirmed MC had altered mental status (AMS). Approximately 71.9% (95CI:68.0%-75.8%) of patients with MC had hypothermia, and 66.2% (95CI:62.3%-70.1%) had a heart rate < 60 bpm. Seven signs (hypoglycaemia, hypotension, hypercarbia, hoarseness, dry skin, constipation, and puffiness) showed both negative and positive predictive values below 70% and were consequently excluded from the diagnostic criteria. Combined with literature reviews and statistical analysis, proposed diagnostic criteria for MC are presented. It is generally recommended to confirm the presence of decreased FT3 and/or FT4 levels as a necessary criterion for establishing a diagnosis of MC. Early recognition, clinical suspicion, prompt thyroid hormone replacement, supportive measures, and appropriate management of coexisting problems remain the cornerstone of managing this fatal endocrine emergency. Future research directions for MC should focus on: clinical validation and refinement of diagnostic criteria, elucidating the pathophysiological mechanism underlying MC, and conducting clinical studies to compare the efficacy of different treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.